We are live on ! Find out more
CM

Crestline Management Portfolio holdings

AUM $46.3M
1-Year Est. Return 48.82%
This Fund
S&P 500
This Quarter Est. Return
+2.53%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$842M
AUM Growth
+$160M
Cap. Flow
+$179M
Cap. Flow %
21.25%
Top 10 Hldgs %
32.27%
Holding
254
New
89
Increased
38
Reduced
24
Closed
97

Top Buys

Rank Stock Value
1
TSM icon
TSMC
TSM
+$12.6M
2
WFC icon
Wells Fargo
WFC
+$12.2M
3
HBAN icon
Huntington Bancshares
HBAN
+$11.7M
4
EXC icon
Exelon
EXC
+$11.1M
5
BTU icon
Peabody Energy
BTU
+$10.7M

Sector Composition

Rank Sector Weight
1 Financials 20.59%
2 Technology 20.4%
3 Healthcare 19.9%
4 Utilities 11.57%
5 Industrials 11.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MLAI
251
DELISTED
McLaren Technology Acquisition Corp. Class A Common Stock
MLAI
-60,500
Closed -$618K
MIT
252
DELISTED
Mason Industrial Technology, Inc.
MIT
-90,000
Closed -$900K
SIVB
253
DELISTED
SVB Financial Group
SIVB
-5,000
Closed -$1.15M
DUET
254
DELISTED
DUET Acquisition Corp. Class A Common Stock
DUET
-99,371
Closed -$1M

Similar funds

Crestline Management's Q1 2023 Portfolio in Review

As of Q1 2023, Crestline Management held 254 positions worth $842M, up 23% from $682M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Crestline Management deployed $179M of net new capital in Q1 2023, opening 89 new positions and adding to 38 existing holdings. Its largest new stake was TSMC: 140,000 shares worth $13M.

By sector, the portfolio is most concentrated in Financials at 21% of assets, down from 23% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $12.4M trimmed.

  • Crestline Management's largest Q1 2023 buy was TSMC: 140,000 shares worth $13M.
  • Crestline Management added most to Wells Fargo in Q1 2023, an estimated $12.2M increase.
  • Crestline Management's biggest Q1 2023 reduction was Denali Therapeutics, cutting an estimated $12.4M.
  • Crestline Management fully exited Progressive in Q1 2023, selling an estimated $8.43M.
  • Crestline Management's ten largest holdings make up 32% of its $842M portfolio in Q1 2023.
  • Crestline Management opened 89 new positions and closed 97 in Q1 2023.
  • Crestline Management's portfolio value rose 23% quarter-over-quarter to $842M.

Based on Crestline Management's 13F filing for Q1 2023, filed 15 May 2023.